Background
Background High rates of osteoHigh rates of osteoporosis in schizophrenia may result from porosis in schizophrenia may result from the prolactin-raising effects of some the prolactin-raising effects of some antipsychotic medication. antipsychotic medication.
Aims Aims To examine bone mineral density
To examine bone mineral density in relation to relevant endocrine variables in relation to relevant endocrine variables in patients with schizophrenia taking in patients with schizophrenia taking prolactin-raising antipsychotics. prolactin-raising antipsychotics.
Method Method Fifty-five patients who had
Fifty-five patients who had been receiving prolactin-raising antibeen receiving prolactin-raising antipsychotic medication for psychotic medication for 4 410 years 10 years underwent dual-energy X-ray underwent dual-energy X-ray absorptiometry of their lumbar and hip absorptiometry of their lumbar and hip bones. Among the endocrine variables bones. Among the endocrine variables assessed were plasma prolactin and sex assessed were plasma prolactin and sex hormones. hormones.
Results
Results Age-related reduced bone Age-related reduced bone mineral density measures were found in mineral density measures were found in 17 (57%) of the male and 8 (32%) of 17 (57%) of the male and 8 (32%) of the female patients. Higher doses of the female patients. Higher doses of medication were associated with medication were associated with increased rates of both hyperproincreased rates of both hyperprolactinaemia and bone mineral density loss. lactinaemia and bone mineral density loss. Bone loss for the whole group was Bone loss for the whole group was correlated with medication dose, and for correlated with medication dose, and for men was inversely correlated with men was inversely correlated with testosterone values. testosterone values.
Conclusions Conclusions These results suggestthat
These results suggestthat patients with schizophrenia on long-term patients with schizophrenia on long-term prolactin-raising antipsychotic medication prolactin-raising antipsychotic medication are at high risk of developing reduced are at high risk of developing reduced bone mineral density as a consequence bone mineral density as a consequence of hyperprolactinaemia-induced of hyperprolactinaemia-induced hypogonadism. hypogonadism.
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A previous study from this group has A previous study from this group has demonstrated that most individuals on demonstrated that most individuals on typical antipsychotic medications have typical antipsychotic medications have pathologically elevated prolactin levels pathologically elevated prolactin levels and, if female, are hypogonadal (Smith and, if female, are hypogonadal (Smith et et al al, 2002) . Hyperprolactinaemia is asso-, 2002) . Hyperprolactinaemia is associated with reduced bone mineral density, ciated with reduced bone mineral density, which is probably mediated by the which is probably mediated by the inhibition exerted by prolactin on the inhibition exerted by prolactin on the hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-gonadal axis and the resulting hypogonadism (Schlecter the resulting hypogonadism (Schlecter et al et al, , 1983) . It is known that osteoporosis is asso-1983). It is known that osteoporosis is associated with schizophrenia (Halbreich ciated with schizophrenia (Halbreich et al et al, , 1995; Bilici 1995; Bilici et al et al, 2002) and several recent , 2002) and several recent review papers have pointed to the potential review papers have pointed to the potential importance of an association between antiimportance of an association between antipsychotic-induced hyperprolactinaemia and psychotic-induced hyperprolactinaemia and osteoporosis (Naidoo osteoporosis (Naidoo et al et al, 2003; Wieck , 2003; Wieck & Haddad, 2003) . The aim of this study & Haddad, 2003) . The aim of this study was to examine the relationship between was to examine the relationship between bone mineral density, prolactin levels bone mineral density, prolactin levels and hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-gonadal axis function using a cross-sectional design in function using a cross-sectional design in individuals with schizophrenia. individuals with schizophrenia.
METHOD METHOD

Study participants Study participants
Male and post-menopausal female patients Male and post-menopausal female patients with a diagnosis of schizophrenia on longwith a diagnosis of schizophrenia on longterm prolactin-raising antipsychotic mediterm prolactin-raising antipsychotic medication cation ( (4 410 years) were eligible for 10 years) were eligible for inclusion in the study. Post-menopausal inclusion in the study. Post-menopausal status was defined as absence of menstruastatus was defined as absence of menstruation for at least 2 years and being tion for at least 2 years and being 4 452 52 years of age. Participants were recruited years of age. Participants were recruited from out-patient clinics attached to from out-patient clinics attached to three psychiatric hospitals: St Ita's and St three psychiatric hospitals: St Ita's and St John of God's Hospital, Dublin and the John of God's Hospital, Dublin and the Maudsley Hospital, Maudsley Hospital, London. Exclusion London. Exclusion criteria included any medications known criteria included any medications known to be associated with the development or to be associated with the development or treatment of osteoporosis or the presence treatment of osteoporosis or the presence of medical disorders known to be risk of medical disorders known to be risk factors for osteoporosis. Patients with a hisfactors for osteoporosis. Patients with a history of eating disorders were also excluded. tory of eating disorders were also excluded. Ethical approval was sought from and Ethical approval was sought from and granted by each hospital involved in the granted by each hospital involved in the study and written informed consent to parstudy and written informed consent to participate in the study was obtained from ticipate in the study was obtained from each participant. each participant.
Clinical assessment Clinical assessment
Clinical assessment included a semiClinical assessment included a semistructured clinical interview with resultant structured clinical interview with resultant DSM-IV diagnoses (American Psychiatric DSM-IV diagnoses (American Psychiatric Association, 1994) . Illness severity was Association, 1994). Illness severity was measured using the Brief Psychiatric Rating measured using the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) Scale (BPRS; Overall & Gorham, 1962) and the Schedule for Assessment of Negaand the Schedule for Assessment of Negative Symptoms (SANS; Andreason, 1983) . tive Symptoms (SANS; Andreason, 1983) . A medical history was obtained detailing A medical history was obtained detailing relevant information, such as a history of relevant information, such as a history of fractures or polydipsia. Each participant fractures or polydipsia. Each participant had a full physical examination, including had a full physical examination, including body mass index evaluation. body mass index evaluation.
A detailed drug history was recorded. A detailed drug history was recorded. In order to have a comparable value for In order to have a comparable value for each patient, medication was converted to each patient, medication was converted to chlorpromazine equivalents (Taylor chlorpromazine equivalents (Taylor et al et al, , 2001 ). The atypical antipsychotics olanza-2001). The atypical antipsychotics olanzapine and risperidone were converted pine and risperidone were converted according to the best pharmacological according to the best pharmacological match for dopamine 2 receptor blockade match for dopamine 2 receptor blockade to typicals: clozapine and haloperidol, to typicals: clozapine and haloperidol, respectively (Seeman, 1992) . A modified respectively (Seeman, 1992) . A modified version of an osteoporosis questionnaire version of an osteoporosis questionnaire was completed for each participant. This was completed for each participant. This questionnaire examines information relequestionnaire examines information relevant to bone mineral density, such as vant to bone mineral density, such as family history, parity, dietary and weightfamily history, parity, dietary and weightbearing exercise habits. bearing exercise habits.
Endocrine assessment Endocrine assessment
A blood sample was drawn from each A blood sample was drawn from each patient to measure oestradiol, propatient to measure oestradiol, progesterone, testosterone, follicle-stimulating gesterone, testosterone, follicle-stimulating hormone, luteinising hormone and sex horhormone, luteinising hormone and sex hormone binding globulin (a marker of gonamone binding globulin (a marker of gonadal hormone concentrations). Plasma dal hormone concentrations). Plasma prolactin, cortisol, thyroid-stimulating horprolactin, cortisol, thyroid-stimulating hormone, thyroxine and triiodothyronine were mone, thyroxine and triiodothyronine were also measured in each patient. Samples also measured in each patient. Samples were collected at random times during the were collected at random times during the day (09.00-18.00 h), spun within 1 hour day (09.00-18.00 h), spun within 1 hour and the frozen serum/plasma was batch and the frozen serum/plasma was batch analysed. Blood sampling was not related analysed. Blood sampling was not related to the timing of meals. to the timing of meals.
Prolactin, oestradiol, luteinising Prolactin, oestradiol, luteinising hormone, hormone, follicle-stimulating hormone, follicle-stimulating hormone, thyroidthyroid-stimulating hormone and thyroxine stimulating hormone and thyroxine levels were measured using levels were measured using time-resolved time-resolved fluoroimmunoassays methods fluoroimmunoassays methods with comwith commercial kits (AutoDELFIA, PerkinElmer, mercial kits (AutoDELFIA, PerkinElmer, Inc.: human hormone references supplied Inc.: human hormone references supplied by Wallac Oy, Turku, Finland). Progesterby Wallac Oy, Turku, Finland). Progesterone, testosterone and sex-hormone-binding one, testosterone and sex-hormone-binding 
Bone mineral density assessment Bone mineral density assessment
Osteoporosis is defined by the World Osteoporosis is defined by the World Health Organization as a bone mineral Health Organization as a bone mineral density of more than 2.5 standard deviadensity of more than 2.5 standard deviations below the mean value for peak bone tions below the mean value for peak bone mass in young adults when measured by mass in young adults when measured by dual-energy X-ray absorptiometry (DEXA) dual-energy X-ray absorptiometry (DEXA) (World Health Organization Study Group, (World Health Organization Study Group, 1994) . The bone mineral density was deter-1994). The bone mineral density was determined in lumbar vertebrae L1-L4 and in mined in lumbar vertebrae L1-L4 and in the femoral neck, trochanteric and intertrothe femoral neck, trochanteric and intertrochanteric regions of the left hip using a chanteric regions of the left hip using a DEXA scan, which is currently the most DEXA scan, which is currently the most precise and widely used method of assessing precise and widely used method of assessing bone mineral density. Bone density is bone mineral density. Bone density is measured in relation to two sets of values measured in relation to two sets of values generated by the DEXA scanner: generated by the DEXA scanner: t t scores scores compare the patients' results with standardcompare the patients' results with standardised peak bone mass of females/males 20-ised peak bone mass of females/males 20-30 years old; and 30 years old; and Z Z scores compare the scores compare the bone mineral density with the average for bone mineral density with the average for her/his age group. Only her/his age group. Only Z Z scores are scores are reported in this paper. reported in this paper.
Statistical analysis Statistical analysis
The SPSS for Windows (1999 version) was The SPSS for Windows (1999 version) was used to analyse the data. Results were used to analyse the data. Results were analysed both for the whole group and analysed both for the whole group and separately for each gender. Independent separately for each gender. Independent t t-tests (two-tailed) were used to identify -tests (two-tailed) were used to identify differences between groups, and crossdifferences between groups, and crosstabulations were performed using tabulations were performed using w w 
RESULTS RESULTS
Demographic data Demographic data
Demographic data are shown in Table 1 . Demographic data are shown in Table 1 . Twenty-five post-menopausal women and Twenty-five post-menopausal women and 30 men were recruited into the study. The 30 men were recruited into the study. The subjects were either of Caucasian ( subjects were either of Caucasian (n n¼46) 46) or African-Caribbean ( or African-Caribbean (n n¼9) ethnicity. 9) ethnicity. There was a significant difference between There was a significant difference between male and female groups in terms of age male and female groups in terms of age ( (P P5 50.01), number of cigarettes smoked 0.01), number of cigarettes smoked per day ( per day (P P5 50.05) and daily exercise taken 0.05) and daily exercise taken ( (P P5 50.001). Females had been exposed to 0.001). Females had been exposed to medication for significantly longer periods medication for significantly longer periods than males ( than males (P P¼0.04). 0.04).
Clinical data Clinical data
No associations were found between bone No associations were found between bone mineral density values and clinical meamineral density values and clinical measures of psychiatric illness (BPRS or SANS), sures of psychiatric illness (BPRS or SANS), or the presence of polydipsia. Among the or the presence of polydipsia. Among the lifestyle variables, only cigarette smoking lifestyle variables, only cigarette smoking was significantly correlated with reduced was significantly correlated with reduced Z Z scores in L4 for the combined group scores in L4 for the combined group ( (r r¼7 70.27, 0.27, P P¼0.04). 0.04).
Endocrine data Endocrine data (seeTable 2) (see Table 2 ) 
Medication
Medication (see Table 3 ) (see Table 3 )
Within the total group, 17 (31%) were reWithin the total group, 17 (31%) were receiving more than one antipsychotic agent. ceiving more than one antipsychotic agent. All patients taking the prolactin-sparing All patients taking the prolactin-sparing antipsychotic olanzapine were also on a antipsychotic olanzapine were also on a conventional depot antipsychotic drug. conventional depot antipsychotic drug.
5 0 4 5 0 4 Thyroid-stimulating hormone (0.5^4.2 mIU/l) Thyroid-stimulating hormone (0.5^4.2 mIU/l) 1.9 (2.6) 1.9 (2.6) 3.1 (5.4) 3.1 (5.4) Thyroxine (8^21pmol/l) Thyroxine (8^21pmol/l) 13.7 (2.5) 13.7 (2.5) 12.9 (2.3) 12.9 (2.3) Participants were divided into two groups: Participants were divided into two groups: those receiving more than the upper limit those receiving more than the upper limit of the of the British National Formulary British National Formulary range range for 'usual maintenance dose' of chlorprofor 'usual maintenance dose' of chlorpromazine (300 mg/day) and those receiving mazine (300 mg/day) and those receiving less than this. There were no significant difless than this. There were no significant differences between these groups in terms of ferences between these groups in terms 
Correlational measures Correlational measures
Hormone levels and bone mineral density Hormone levels and bone mineral density
The free testosterone index (testosterone/ The free testosterone index (testosterone/ sex-hormone-binding globulin) was corresex-hormone-binding globulin) was correlated with the bone mineral density lated with the bone mineral density Z Z sumsummary lumbar score (see Fig. 1 ). The mary lumbar score (see Fig. 1 ). The summary lumbar score is a DEXAsummary lumbar score is a DEXAgenerated calculation of bone mineral generated calculation of bone mineral density scores from L1 to L4 for each indidensity scores from L1 to L4 for each individual, and thus reflects the total bone vidual, and thus reflects the total bone density in the lumbar spine. This correladensity in the lumbar spine. This correlation was not found in the hip region. There tion was not found in the hip region. There was no statistical relationship between was no statistical relationship between prolactin, follicle-stimulating hormone, prolactin, follicle-stimulating hormone, luteinising hormone, oestradiol, proluteinising hormone, oestradiol, progesterone or thyroid hormones and bone gesterone or thyroid hormones and bone mineral density values. mineral density values.
Chlorpromazine equivalents and bone mineral Chlorpromazine equivalents and bone mineral density density (see Table 4 and Fig. 2 ) (see Table 4 and Fig. 2) There was a significant correlation between There was a significant correlation between chlorpromazine equivalence scores and chlorpromazine equivalence scores and both lumbar-weighted scores ( both lumbar-weighted scores (r r¼0.4, 0.4, P P¼0.002) and combined lumbar-and hip-0.002) and combined lumbar-and hipweighted scores ( weighted scores (r r¼0.35, 0.35, P P¼0.009). 0.009).
Multivariate regression analysis Multivariate regression analysis
In a multivariate regression analysis for In a multivariate regression analysis for both genders combined examining clinical, both genders combined examining clinical, endocrine and lifestyle variables, only the endocrine and lifestyle variables, only the chlorpromazine equivalence scores were chlorpromazine equivalence scores were statistically predictive of reduced bone statistically predictive of reduced bone mineral density scores at L1-L4 mineral density scores at L1-L4 ( (P P5 50.0001). When genders were analysed 0.0001). When genders were analysed separately, no further factors were predicseparately, no further factors were predictive of bone mineral density loss in tive of bone mineral density loss in females. In the male group the free testosfemales. In the male group the free testosterone index was also predictive of low terone index was also predictive of low bone mineral density in L1-L4 ( bone mineral density in L1-L4 (P P¼0.03); 0.03); and sex-hormone-binding globulin almost and sex-hormone-binding globulin almost reached significance as a predictive value reached significance as a predictive value ( (P P¼0.06). 0.06).
5 0 5 5 0 5 Fig. 1 Fig. 1 Scatterplot of summary lumbar bone mineral density Scatterplot of summary lumbar bone mineral density Z Z scores and free testosterone index levels in scores and free testosterone index levels in males.There is a significant correlation between free testerosterone indices in males and the summary lumbar males.There is a significant correlation between free testerosterone indices in males and the summary lumbar Z Z scores ( scores (r r¼0.5, 0.5, P P¼0.01). Free testosterone index: normal reference range 20^350 nmol/l. 0.01). Free testosterone index: normal reference range 20^350 nmol/l. 
DISCUSSION DISCUSSION
Main findings Main findings
This study was designed to evaluate the This study was designed to evaluate the long-term effects of prolactin-raising antilong-term effects of prolactin-raising antipsychotic medication on bone metabolism psychotic medication on bone metabolism in patients with a diagnosis of schizoin patients with a diagnosis of schizophrenia. Both male and female groups had phrenia. Both male and female groups had high rates of hyperprolactinaemia (62%) high rates of hyperprolactinaemia (62%) and had a range of osteopenic and osteoand had a range of osteopenic and osteoporotic measures that fell outside the porotic measures that fell outside the normal age-related values. Age-consistent normal age-related values. Age-consistent osteopenia or osteoporosis was found in osteopenia or osteoporosis was found in 57% and 32% of the male and female 57% and 32% of the male and female groups, respectively. High levels of medigroups, respectively. High levels of medication were associated with high prolactin cation were associated with high prolactin levels and reduced bone mineral density levels and reduced bone mineral density scores. In a multivariate analysis for both scores. In a multivariate analysis for both genders combined, only treatment dose regenders combined, only treatment dose remained associated with bone loss but low mained associated with bone loss but low free testosterone index values were addifree testosterone index values were additionally correlated with bone loss in the tionally correlated with bone loss in the male group. male group. The findings of associations between The findings of associations between chlorpromazine equivalents scores and chlorpromazine equivalents scores and both prolactin levels and low bone mineral both prolactin levels and low bone mineral density values is novel. Antipsychotic medidensity values is novel. Antipsychotic medication blocks the type 2 dopamine (D cation blocks the type 2 dopamine (D 2 2 ) ) receptors on the lactotrophs of the anterior receptors on the lactotrophs of the anterior pituitary, thus releasing these cells from pituitary, thus releasing these cells from dopamine inhibition and consequently supdopamine inhibition and consequently suppression of prolactin secretion (Dickson pression of prolactin secretion (Dickson et al et al, 2000) . One positron emission , 2000) . One positron emission tomography study has demonstrated that tomography study has demonstrated that hyperprolactinaemia is likely to occur when hyperprolactinaemia is likely to occur when central D central D 2 2 receptor occupancy exceeds receptor occupancy exceeds 72% (Kapur 72% (Kapur et al et al, 2000) . This physiologi-, 2000) . This physiological process may underlie the strong statistical process may underlie the strong statistical relationship between chlorpromazine cal relationship between chlorpromazine equivalence scores and prolactin levels. equivalence scores and prolactin levels. Any potent D Any potent D 2 2 -blocking antipsychotic, -blocking antipsychotic, whether 'typical' or 'atypical', is likely to whether 'typical' or 'atypical', is likely to cause prolactin secretion and thus all pacause prolactin secretion and thus all patients in this study taking the antipsychotic tients in this study taking the antipsychotic risperidone had hyperprolactinaemia, in risperidone had hyperprolactinaemia, in keeping with the established prolactinkeeping with the established prolactinraising profile of this drug (Kinon raising profile of this drug (Kinon et al et al, , 2003 (Kinon et al et al, , ). 2003 .
Bone strength is largely determined by Bone strength is largely determined by calcium content and rate of bone loss, calcium content and rate of bone loss, which in turn is determined by genetic which in turn is determined by genetic factors, weight, ethnicity, diet, exercise, factors, weight, ethnicity, diet, exercise, hormone status and gender (Hobson & hormone status and gender (Hobson & Ealston, 2001) . Although the physiological Ealston, 2001). Although the physiological processes mediating bone loss are compliprocesses mediating bone loss are complicated, the most common cause of bone loss cated, the most common cause of bone loss is sex hormone deficiency (Schlecter is sex hormone deficiency (Schlecter et al et al, , 1983; Davies 1983; Davies et al et al, 1995) . The bone loss , 1995). The bone loss associated with hyperprolactinaemic states, associated with hyperprolactinaemic states, whether prolactin is elevated pathologically whether prolactin is elevated pathologically or physiologically, is probably mediated by or physiologically, is probably mediated by secondary hypogonadism, although other secondary hypogonadism, although other mechanisms have been proposed (see Wieck mechanisms have been proposed (see Wieck & Haddad, 2003) . Prolactin interferes with & Haddad, 2003) . Prolactin interferes with the pulsatile secretion of gonadotrophinthe pulsatile secretion of gonadotrophinreleasing hormone from the hypothalamus releasing hormone from the hypothalamus and may also have a peripheral effect and may also have a peripheral effect at the level of the gonads, inhibiting at the level of the gonads, inhibiting some luteinising hormone-and folliclesome luteinising hormone-and folliclestimulating hormone-mediated effects. stimulating hormone-mediated effects.
The association of low free testosterone The association of low free testosterone index with osteoporosis in this study index with osteoporosis in this study supports hyperprolactinaemic-induced hyposupports hyperprolactinaemic-induced hypogonadism as being the relevant pathological gonadism as being the relevant pathological process in the male patients because the process in the male patients because the association was present in males only in association was present in males only in the gender-specific multivariate regression the gender-specific multivariate regression analysis. Free testosterone index values reanalysis. Free testosterone index values represent the biologically active, or unbound, present the biologically active, or unbound, part of the circulating testosterone. Bone part of the circulating testosterone. Bone loss was associated with the free testosterloss was associated with the free testosterone index in the lumbar spine region only, one index in the lumbar spine region only, and not the hip joint. The absence of bone and not the hip joint. The absence of bone loss in the hip joint in this relatively young loss in the hip joint in this relatively young male sample is in keeping with the fact that male sample is in keeping with the fact that bone loss typically first occurs in the spine bone loss typically first occurs in the spine region (in 92% of individuals). region (in 92% of individuals).
The female group was post-menopausal The female group was post-menopausal and thus uniformly hypogonadal, preand thus uniformly hypogonadal, preventing an venting an a priori a priori hypothesis of an associahypothesis of an association between gonadal status and bone tion between gonadal status and bone measures to be tested. A previous study by measures to be tested. A previous study by our group found that 75% ( our group found that 75% (n n¼15) of a 15) of a group of premenopausal females with a group of premenopausal females with a diagnosis of schizophrenia on prolactindiagnosis of schizophrenia on prolactinraising antipsychotics were hyperproraising antipsychotics were hyperprolactinaemic and high prolactin levels were lactinaemic and high prolactin levels were negatively correlated with both oestradiol negatively correlated with both oestradiol and progesterone levels (Smith and progesterone levels (Smith et al et al, , 2002) . A recently published study has also 2002). A recently published study has also reported associations between high proreported associations between high prolactin levels and low key reproductive lactin levels and low key reproductive hormone levels in males and females hormone levels in males and females on antipsychotic medication (Kinon on antipsychotic medication (Kinon et al et al, , 2003) . 2003).
Osteoporosis and schizophrenia Osteoporosis and schizophrenia
Decreased bone mineral density in psychiDecreased bone mineral density in psychiatric patients has been recognised for some atric patients has been recognised for some time but only recently investigated. Cases time but only recently investigated. Cases of osteoporosis have been reported in of osteoporosis have been reported in women and men with anorexia nervosa, women and men with anorexia nervosa, chronic alcoholism, depression and schizochronic alcoholism, depression and schizophrenia (Delva phrenia (Delva et al et al, 1989; Abraham , 1989; Abraham et al et al, , 1995; Halbreich 1995; Halbreich et al et al, 1995) . Halbreich , 1995). Halbreich et et al al (1995) reported that patients, particu-(1995) reported that patients, particularly males with major depressive disorder, larly males with major depressive disorder, schizophrenia, schizoaffective disorders, schizophrenia, schizoaffective disorders, mania and adjustment disorders, had signifmania and adjustment disorders, had significantly decreased bone mineral density. icantly decreased bone mineral density. Original reports of osteoporosis in people Original reports of osteoporosis in people with schizophrenia suggested an associawith schizophrenia suggested an association with polydipsia (Delva tion with polydipsia (Delva et al et al, 1989) , 1989) but we found no correlation between but we found no correlation between polydipsia and reduced bone mineral polydipsia and reduced bone mineral density. Bilici density. Bilici et al et al (2002 Bilici et al et al ( ) reported in-(2002 reported increased rates of reduced lumbar spine creased rates of reduced lumbar spine 5 0 6 5 0 6 bone mineral density scores in a group bone mineral density scores in a group of patients with schizophrenia taking of patients with schizophrenia taking 'classical' antipsychotic medication com-'classical' antipsychotic medication compared with a group pared with a group on atypical antipsyon atypical antipsychotics and a healthy control group. That chotics and a healthy control group. That study did not examine relative prolactin study did not examine relative prolactin levels in the groups but all the patients in levels in the groups but all the patients in the 'classical' antipsychotic group were on the 'classical' antipsychotic group were on prolactin-raising agents, whereas 38% in prolactin-raising agents, whereas 38% in the atypical group ( the atypical group (n n¼15) were on 15) were on prolactin-sparing agents. Previous studies prolactin-sparing agents. Previous studies have not specifically addressed a possible have not specifically addressed a possible association between osteoporosis and antiassociation between osteoporosis and antipsychotic-induced hyperprolactinaemia, psychotic-induced hyperprolactinaemia, but more recent re but more recent reviews have focused on views have focused on the possibility of such a the possibility of such a relationship relationship (Naidoo (Naidoo et al et al, 2003; Wieck & Haddad, , 2003; Wieck & Haddad, 2003 ). 2003 .
Other established risk factors, such as Other established risk factors, such as high alcohol intake and cigarette smoking, high alcohol intake and cigarette smoking, could possibly account for the high rates could possibly account for the high rates of osteopenia/osteoporosis found in this of osteopenia/osteoporosis found in this sample with schizophrenia. We did find a sample with schizophrenia. We did find a correlation between bone mineral density correlation between bone mineral density scores in the lumbar spine and smoking, scores in the lumbar spine and smoking, but this significance was lost in the multibut this significance was lost in the multivariate analysis, suggesting that the medivariate analysis, suggesting that the medication-related risk factors were more cation-related risk factors were more significant. There was no association besignificant. There was no association between alcohol intake and any of the bone tween alcohol intake and any of the bone measures. Immobility is an unlikely cause measures. Immobility is an unlikely cause of reduced bone mineral density even in of reduced bone mineral density even in individuals with negative symptoms of individuals with negative symptoms of schizophrenia because activity levels inschizophrenia because activity levels involved in routine daily living are sufficient volved in routine daily living are sufficient to retard bone mineral density loss in to retard bone mineral density loss in weight-bearing bones. It is unknown to weight-bearing bones. It is unknown to what degree decreased exposure to sunwhat degree decreased exposure to sunshine and dietary deficiency contribute to shine and dietary deficiency contribute to reduced bone mineral density in patients reduced bone mineral density in patients with chronic mental illnesses, but all partiwith chronic mental illnesses, but all participants in our study indicated on the osteocipants in our study indicated on the osteoporosis questionnaire that they had porosis questionnaire that they had adequate intake of calcium in their diet. adequate intake of calcium in their diet. Low body mass index is another established Low body mass index is another established risk factor for bone mineral loss, but all risk factor for bone mineral loss, but all participants in this study were overweight participants in this study were overweight with a mean body mass index bordering with a mean body mass index bordering on obese. on obese.
It is conceivable that bone loss found in It is conceivable that bone loss found in these people may be related to a metabolic these people may be related to a metabolic disorder that is part of the syndrome of disorder that is part of the syndrome of schizophrenia rather than the endocrine schizophrenia rather than the endocrine consequences of antipsychotic medication. consequences of antipsychotic medication. This is unlikely, given the findings of signifThis is unlikely, given the findings of significant associations between bone loss icant associations between bone loss measures and medication and endocrine measures and medication and endocrine variables, and the absence of associations variables, and the absence of associations between clinical symptom scores and bone between clinical symptom scores and bone mineral density measures. mineral density measures.
Osteoporosis: morbidity Osteoporosis: morbidity and mortality and mortality According to the World Health OrganizaAccording to the World Health Organization, osteoporosis affects 30% of women tion, osteoporosis affects 30% of women over the age of 50 years, with the risk of over the age of 50 years, with the risk of hip fracture increasing 2.6-fold for each hip fracture increasing 2.6-fold for each standard deviation decrease in hip bone standard deviation decrease in hip bone mineral density. Hip fracture complications mineral density. Hip fracture complications include a mortality of 20% in one year, include a mortality of 20% in one year, with only 25% of patients recovering full with only 25% of patients recovering full function and 25% requiring long-term infunction and 25% requiring long-term institutional care (Hobson & Ealston, 2001) . stitutional care (Hobson & Ealston, 2001) .
The absence of evidence associating The absence of evidence associating prolactin-raising antipsychotic drug use prolactin-raising antipsychotic drug use with bone loss may explain why drugs such with bone loss may explain why drugs such as glucocorticoids, lithium, anticonas glucocorticoids, lithium, anticonvulsants, thyroxine and gonadotrophinvulsants, thyroxine and gonadotrophinreleasing hormone antagonists are releasing hormone antagonists are listed by listed by the World Health Organization and the the World Health Organization and the Royal College of Physicians as being assoRoyal College of Physicians as being associated with the development of osteoporociated with the development of osteoporosis but antipsychotic drugs are not (World sis but antipsychotic drugs are not (World Health Organization Study Group, 1994) . Health Organization Study Group, 1994) .
Limitations of this study Limitations of this study
The study is limited by the absence of a The study is limited by the absence of a control group of patients with schizocontrol group of patients with schizophrenia who were receiving prolactinphrenia who were receiving prolactinsparing antipsychotics. We were unable to sparing antipsychotics. We were unable to recruit the latter group because prolactinrecruit the latter group because prolactinsparing antipsychotics have not been widely sparing antipsychotics have not been widely in use for the time duration required for this in use for the time duration required for this study. study. A potential limitation of the study was A potential limitation of the study was the collection of blood samples at random the collection of blood samples at random times during working hours, given that times during working hours, given that Patients on long-term prolactin-raising antipsychotics are at high risk of developing osteoporosis, suggesting that these drugs are an unidentified risk factor for this osteoporosis, suggesting that these drugs are an unidentified risk factor for this disease. disease. The study did not have a comparison group: either individuals with schizophrenia who had been exposed to prolactin-sparing antipsychotic medication, or a healthy who had been exposed to prolactin-sparing antipsychotic medication, or a healthy group without psychiatric illness. group without psychiatric illness. The high rates of bone loss in this group could have been contributed to by other risk factors prevalent in this population, such as smoking, poor diet and inactivity, or risk factors prevalent in this population, such as smoking, poor diet and inactivity, or could be related to a metabolic disorder that is part of the syndrome of schizophrenia could be related to a metabolic disorder that is part of the syndrome of schizophrenia rather than the endocrine consequences of antipsychotic medication. rather than the endocrine consequences of antipsychotic medication. The female group were post-menopausal, preventing any associations between gonadal status and other variables from being assessed. gonadal status and other variables from being assessed.
LIMITATIONS LIMITATIONS
